Article

Mechanism of vascular relaxation by cholinomimetic drugs with special reference to pilocarpine and arecoline.

Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus 43210, USA.
Journal of Ocular Pharmacology and Therapeutics (Impact Factor: 1.42). 02/2002; 18(1):25-34. DOI: 10.1089/108076802317233180
Source: PubMed

ABSTRACT The muscarinic receptor-mediated and non-muscarinic vascular effects of cholinomimetic drugs used in glaucoma were quantified. On the isolated rat aorta, the vascular tone induced by phenylephrine is functionally antagonized by cholinomimetic drugs. Based on EC50, the relative order of potency for the endothelium-dependent vascular relaxation was acetylcholine (0.05 microM) 1 > (+/-)-methacholine (0.35 microM) 1/7 > carbachol (0.63 microM) 1/12 > (+/-)-aceclidine (1.26 microM) 1/25. The maximal effects of the four agonists varied between 82-87%. The muscarinic vascular relaxation of 0.03 microM to 100 microM pilocarpine was less than 15%. At high concentrations, pilocarpine had 1/20.000 the vascular activity of acetylcholine. Physostigmine failed to potentiate the vascular relaxation of exogenous acetylcholine, indicating the absence of acetylcholine esterase in the tissue. Arecoline, with an EC50 of 7.76 microM, was partly sensitive to the removal of the endothelium. Atropine treatment did not block the vascular effect of high concentrations of pilocarpine. Atropine, as expected, blocked the vascular effects of carbachol with K(B) = 3.2 nM. Pilocarpine produces vascular relaxation by its competition with spasmogens like phenylephrine, oxymetazoline, vasopressin or latanoprost. Arecoline also shares these properties with pilocarpine in the blood vessel. The molecular mechanism of the vascular effects as well as ocular clinical implications of cholinomimetic drugs is discussed.

0 Followers
 · 
143 Views
 · 
0 Downloads
  • [Show abstract] [Hide abstract]
    ABSTRACT: The main objective of this investigation was to compare the acetylcholine potentiating action of huperzine-A with acetylcholinesterase inhibitor physostigmine on the frog rectus abdominus muscle, rat phrenic nerve diaphragm preparation, guinea pig ileum and human iris sphincter muscle. In vitro on the frog rectus abdominus muscle, microM of each alkaloid, incubated for 10 min, shifted the acetylcholine concentration response curve to the left. At EC(50) level, physostigmine potentiated acetylcholine response by 4-fold. The potentiation by huperzine-A was 40-fold. The acetylcholine maximum effect, relative to the control, increased to approximately 130% by each alkaloid. Neurally mediated twitch contraction of the rat diaphragm, a skeletal muscle at 1 microM was also potentiated more by huperzine-A than that by physostigmine. Neuromuscular block by (+)-tubocurarine was reversed more easily by huperzine-A than that by physostigmine. On guinea pig ileum, a 30 nM concentration of each alkaloid incubated for 5 min potentiated acetylcholine (10 nM) by 42%, and 33% for huperzine-A and physostigmine respectively. The difference in potentiation between the alkaloids was not significant. At 300 nM of each alkaloid, intrinsic indirect contractions were observed on the ileum, where the rate of contraction by huperzine-A was faster than that by physostigmine. On the iris sphincter, huperzine-A and physostigmine produced a concentration-dependent effect. Maximum effect after each alkaloid was achieved at 30 microM. Potentiation of acetylcholine response by 0.3 microM huperzine-A after a 10-min incubation was greater than that achieved by physostigmine at an equivalent concentration on the contralateral iris sphincter. In summary, huperzine-A exhibits greater acetylcholine potentiating activity on vertebrate muscles than that produced by physostigmine. The results are discussed in relation to the potential therapeutic value of huperzine-A.
    Journal of Ocular Pharmacology and Therapeutics 05/2003; 19(2):135-43. DOI:10.1089/108076803321637663 · 1.42 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Arecoline (methyl-1,2,5,6-tetrahydro-1-methyl nicotinate) is an alkaloid found in the areca catechu nut which is a major component of the 'betel quid' chewed by a large proporation of the population in India, South Asia and the South Pacific islands. It is commonly associated with the development of oral leukoplakia, oral submucous fibrosis and oral cancer. We have developed a new ion-pairing reversed-phase high-performance liquid chromatographic (HPLC) method for the determination of arecoline in saliva, using arecaidine (1,2,5,6-tetrahydro-1-methylnicotinic acid) as an internal standard. The optimal wavelength was established using UV absorbance scans. It was showed that 215 nm is the optimal wavelength to maximise the signal in detecting arecoline in the mobile phase. Arecoline was extracted from saliva with hexane-isoamyl alcohol (1%) and reconstituted with mobile phase for HPLC analysis. The developed method is an easy and reliable method of determining arecoline concentrations in saliva. Sensitivity, specificity, precision, accuracy and reproducibility of the method were demonstrated to be satisfactory for measuring the arecoline level.
    Journal of Chromatography A 05/2004; 1032(1-2):93-5. DOI:10.1016/j.chroma.2003.11.076 · 4.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The parasympathetic and sympathetic divisions of the autonomic nervous system are involved in homeostatic control of a wide variety of ocular functions, including accommodation, pupillomotor control, lacrimation, eyelid position, and aqueous humor production. Familiarity with the functional anatomy of the autonomic nervous system is paramount to the understanding and application of the large number of autonomic drugs used in veterinary ophthalmology. The cholinergic and adrenergic agents discussed in this article are commonly employed to facilitate routine ophthalmic examination, in the diagnosis of autonomic dysfunction, and in the treatment of a variety of ocular diseases.
    Veterinary Clinics of North America Small Animal Practice 06/2004; 34(3):777-800. DOI:10.1016/j.cvsm.2003.12.011 · 1.04 Impact Factor
Show more